Pomalidomide - Celgene Corporation

Drug Profile

Pomalidomide - Celgene Corporation

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; Pomalyst

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cytokine modulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Brain cancer; Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • Phase I Waldenstrom's macroglobulinaemia
  • No development reported Myelofibrosis; Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer

Most Recent Events

  • 10 Aug 2018 Bristol-Myers Squibb withdraws a phase II trial due to issues around the FDA hold on PD-1/PD-L1 drugs in combination with IMIDs for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03227432)
  • 24 Jun 2018 Biomarkers information updated
  • 20 Jun 2018 Millennium Pharmaceuticals, Celgene and the Alliance for Clinical Trials in Oncology re-initiates a phase I/II trial for Multiple myeloma (Second-line, Combination therapy) in USA (NCT02004275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top